IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024. In the quarter to June 2026, revenue fell 19.7%, EPS fell 100.0%, free cash flow fell 103.3% and total debt rose 713.5%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
Follow IGC
IGC Pharma, Inc. (IGC) EV/Sales
As of 16 October 2026, IGC Pharma, Inc. (IGC) trades at a EV/Sales of 23.4×. Over the past ten years it has ranged from −3.4× (December 2018) to 309× (July 2021); the current reading is higher than 66% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 17.4× | (14.13%) |
| FY2024 | 20.3× | 24.98% |
| FY2023 | 16.2× | (82.65%) |
| FY2022 | 93.7× | 37.72% |
| FY2021 | 68.0× | 3,569.44% |
| FY2020 | 1.9× | (79.39%) |
| FY2019 | 9.0× | 42.18% |
| FY2018 | 6.3× | (70.48%) |
| FY2017 | 21.4× | 1,594.42% |
| FY2016 | 1.3× | 6.15% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 25.3× | 12.42% |
| Mar 2026 | 22.5× | (33.05%) |
| Sep 2025 | 33.6× | 74.35% |
| Jun 2025 | 19.3× | 10.40% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | −7.0× |
| PLRZ Polyrizon Ltd. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| BYSI BeyondSpring Inc. compare | 13.8× |
| ABVC ABVC BioPharma, Inc. compare | 19.6× |
| IGC IGC Pharma, Inc. | 23.4× |
| MCRB Seres Therapeutics, Inc. compare | 58.8× |
| IBO Impact Biomedical Inc. compare | 881× |
| CYAD Celyad SA compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)